Maynard Um
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens
-
-
-
-
-
-
-
CRISPR Therapeutics reports early zugo-cel results in autoimmune diseases
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Raised to $50 at RBC Capital
-
-
-
-
-
-
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Raised to $80 at H.C. Wainwright
-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on CRISPR Therapeutics (CRSP)
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on CRISPR Therapeutics (CRSP)
-
430,013 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

